23.04.2012 - AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)